Loading clinical trials...
Loading clinical trials...
A Phase III, Dose-Response Evaluation of the Efficacy and Safety of CLONICEL® (Clonidine HCl Sustained Release) vs. Placebo in the Treatment of Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
Conditions
Interventions
high dose clonidine HCl sustained release
low dose clonidine HCl sustained release
+1 more
Locations
13
United States
Gainesville, Florida, United States
Jacksonville, Florida, United States
Miami, Florida, United States
Orlando, Florida, United States
Rochester Hills, Michigan, United States
Clementon, New Jersey, United States
Start Date
October 1, 2007
Primary Completion Date
August 1, 2008
Completion Date
August 1, 2008
Last Updated
March 24, 2010
NCT07478458
NCT06685601
NCT06910605
NCT05957055
NCT07426302
NCT07339696
Lead Sponsor
Addrenex Pharmaceuticals, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions